Form 4: AN2 Therapeutics Director Kabeer Aziz Acquires Shares as Non-Cash Compensation

AN2 Therapeutics, Inc. Director Kabeer Aziz acquired 11,875 shares of common stock on July 10, 2025, as non-cash compensation, increasing his total beneficial ownership.

Summary

• Kabeer Aziz, a Director of AN2 Therapeutics, Inc. (ANTX), acquired 11,875 shares of common stock on July 10, 2025.
• The acquired shares were issued in lieu of cash compensation under the company's non-employee director compensation policy and vested immediately upon issuance.
• Following this transaction, Kabeer Aziz directly owns 30,552 shares of common stock.
• He also indirectly beneficially owns 1,995,958 shares held by Adjuvant Global Health Technology Fund, L.P., and 377,542 shares held by Adjuvant Global Health Technology Fund DE, L.P.
• As Secretary of Adjuvant Capital Management, L.L.C., the sole general partner of the general partner for both Adjuvant Global Health Technology Funds, Kabeer Aziz may be deemed to share voting and dispositive power over these indirectly held securities, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director as compensation is generally a positive signal, indicating alignment of interests and confidence in the company. The transaction itself is routine for a Form 4.

Positives

• Director Kabeer Aziz received 11,875 shares of common stock as compensation, which aligns his interests with those of shareholders.
• The shares vested immediately, providing immediate ownership to the director.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an insider transaction, specifically a director's acquisition of shares as compensation. Such transactions are common across all industries as part of executive and director compensation plans, aligning their interests with shareholders. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The practice of issuing shares in lieu of cash compensation to non-employee directors is a common corporate governance practice across various industries, including biotechnology, to align director incentives with long-term shareholder value.
• This transaction is a standard equity compensation event and does not provide specific comparable companies or projects.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director aligns their interests with shareholders, potentially signaling confidence in the company's future.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Kabeer Aziz, Director, SEC Form 4, Insider Transaction, Stock Acquisition, Equity Compensation, Beneficial Ownership